Abstract
Gene delivery is a rapid growth area for a range of therapeutic applications; however progress is being held back by manufacturing considerations and this in turn is a reflection of the need for engineering, delivery, genetic and clinical knowledge to be incorporated into a single programme. Here we will use our interdisciplinary consortium to develop a project whereby nanogels are used to deliver genetic material to the brain as a novel method of non-viral delivery for the treatment of CNS disorders. We will provide a seamless programme that incorporates continuous manufacture via microfluidics, formulation and capacity optimisation, cellular transfection and clinical efficacy using in vivo models.
References
Whitely et al., 2021 “Microfluidic synthesis of protein-loaded nanogels in a coaxial flow reactor using a design of experiments approach” Nanoscale Advances
https://doi.org/10.1039/D0NA01051K
Snowball et al., 2019 “Epilepsy Gene Therapy Using an Engineered Potassium Channel” Journal of Neuroscience
https://doi.org/10.1523/JNEUROSCI.1143-18.2019
Massaro et al., 2018 “Fetal gene therapy for neurodegenerative disease of infants” Nature Medicine
https://doi. org/10.1038/s41591-018-0106-7
Valitov et al., 2020 “Effect of acoustic streaming on continuous flow sonocrystallization in millifluidic channels” Chemical Engineering Journal
http://dx.doi.org/10.1016/j.cej.2019.122221
Tawfik et al., 2021 “In Vitro and In Vivo Biological Assessment of Dual Drug-Loaded Coaxial Nanofibers for the Treatment of Corneal Abrasion” International Journal of Pharmaceutics
https://doi.org/10.1016/j.ijpharm.2021.120732